Article
Biochemistry & Molecular Biology
Hosub Park, Hwangkyu Son, Hyebin Cha, Kihyuk Song, Seongsik Bang, Seungyun Jee, Hyunsung Kim, Jaekyung Myung, Su-Jin Shin, Chihwan Cha, Min Sung Chung, Seungsam Paik
Summary: This study found that low ASAP1 expression was associated with worse recurrence-free survival in invasive breast cancer, particularly in ER-positive cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Mingkun Zhang, Yuan Qin, Niuniu Hou, Fuqing Ji, Zhihao Zhang, Juliang Zhang
Summary: This study aimed to establish a nomogram for accurately predicting the overall survival (OS) of patients with non-metastatic invasive micropapillary breast carcinoma (IMPC). Data from 429 patients in the Surveillance, Epidemiology, and End Results (SEER) database were analyzed to establish a nomogram for predicting OS at 3, 5, and 8 years. The nomogram showed good calibration and predictive accuracy in both the training and validation cohorts, and could help optimize treatment strategies based on individual risk factors.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Qing-Feng Chen, Lei Chang, Qun Su, Ying Zhao, Bin Kong
Summary: The study revealed that serum sCLU protein levels were significantly higher in IBC patients compared to healthy controls, and correlated with tumor stage, lymph node metastasis, overall survival, and disease-free survival. Serum sCLU levels can serve as effective indicators for diagnosis and chemotherapy sensitivity evaluation in patients with IBC.
Article
Oncology
Khloud A. Elsharawy, Maryam Althobiti, Omar J. Mohammed, Abrar I. Aljohani, Michael S. Toss, Andrew R. Green, Emad A. Rakha
Summary: NOP10 is a key factor in ribosome biogenesis and telomere maintenance, and its high expression is significantly associated with aggressive features in breast cancer, especially in the triple-negative breast cancer subtype. High NOP10 protein expression is an independent predictor of poor outcome, shorter survival, and higher risks of death and distant metastasis in chemotherapy-treated patients. This suggests that NOP10 may serve as a potential prognostic biomarker and predictive indicator for chemotherapy resistance in breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Nazia Riaz, Tiffany Jeen, Timothy J. Whelan, Torsten O. Nielsen
Summary: Radiation therapy is commonly used for breast cancer patients who undergo breast-sparing surgery. Recent advancements in diagnosis and treatment have greatly improved breast cancer outcomes, with a 5-year survival rate approaching 100% for patients diagnosed at stage I with favorable clinical and molecular features. This review discusses ongoing research to identify low-risk cancer patients who may not require radiation therapy or can receive lower intensity treatments. The review also examines clinical trials exploring the effects of radiation therapy on patients' immune responses and the potential use of circulating cancer cells to guide radiation decisions.
Article
Cell Biology
Maria Belen Giorello, Leandro Marcelo Martinez, Francisco Raul Borzone, Maria del Rosario Padin, Maria Florencia Mora, Ina Sevic, Laura Alaniz, Maria de Lujan Calcagno, Hernan Garcia-Rivello, Alejandra Wernicke, Vivian Labovsky, Norma Alejandra Chasseing
Summary: This study found that high CD105 expression in cancer-associated fibroblasts in early breast cancer patients is significantly associated with the occurrence of metastasis, particularly bone metastasis. High CD105 expression is also associated with shorter metastasis-free survival, bone metastasis-free survival, and overall survival. CD105 expression is an independent prognostic factor for metastasis-free survival, bone metastasis-free survival, and overall survival.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Oncology
Yingrong Shi, Si Chen, Huijuan Xing, Guanglie Jiang, Nan Wu, Qiannan Liu, Norihiro Sakamoto, Takayoshi Kuno, Reiko Sugiura, Qinghuan Xiao, Feng Jin, Yue Fang, Fan Yao
Summary: Recent studies have shown that the tumor microenvironment plays a crucial role in breast cancer development, progression, and therapeutic response. The immune/stromal/ESTIMATE scores calculated by the ESTIMATE algorithm can reflect the tumor microenvironment. This study analyzed the correlation between immune/stromal/ESTIMATE scores and invasive breast cancer prognosis, and identified high-frequency differential expression genes (HF-DEGs) associated with the tumor microenvironment that have prognostic value. The results suggest that these HF-DEGs may serve as potential biomarkers and therapeutic targets for invasive breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Evelyne Guay, Erin Cordeiro, Amanda Roberts
Summary: In this study, 140 young women with non-metastatic, non-inflammatory invasive breast cancer were reviewed. The majority underwent surgery first, while those who received neoadjuvant chemotherapy were more likely to have abnormal lymph nodes and larger tumor sizes. Patients receiving neoadjuvant chemotherapy had a shorter time to treatment.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Magno Belem Cirqueira, Carolina Rodrigues Mendonca, Matias Noll, Leonardo Ribeiro Soares, Maria Auxiliadora de Paula Carneiro Cysneiros, Regis Resende Paulinelli, Marise Amaral Reboucas Moreira, Ruffo Freitas-Junior
Summary: The role of PD-L1 expression in breast cancer remains controversial, with association with age, lymph node status, hormone receptor expression, Ki67 levels, and HER2 status. PD-L1 positivity is linked to worse overall survival (OS) but does not significantly affect disease-free survival (DFS).
Article
Oncology
Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lubbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark
Summary: In HER2-negative breast cancer patients, T-DM1 treatment may be more effective than trastuzumab.
Article
Immunology
Xi Cao, Yidong Zhou, Feng Mao, Yan Lin, Xingtong Zhou, Qiang Sun
Summary: This study investigated the correlation between Siglec15 and breast cancer and found that high expression of Siglec15 was associated with better prognosis, while low expression was associated with worse prognosis. Three Siglec15-related subtypes of breast cancer were identified, providing important insights into the immunological function and significance of Siglec15 in breast cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Umaima Al-Alem, Garth H. Rauscher, Qais Al Alem, Andre Kajdacsy-Balla, Abeer M. Mahmoud
Summary: We previously observed a reduction in glucocorticoid receptor (GCR) protein expression in invasive breast carcinoma compared to normal breast tissue. In this study, we evaluated the levels of serum/glucocorticoid-regulated kinase 1 (SGK1) and B-cell lymphoma 2 (Bcl-2) in primary breast cancer tissue. SGK1 expression was higher and Bcl-2 expression was lower in breast cancer tissue compared to normal breast tissue. Understanding these molecular alterations and their relationship to clinicopathologic factors is crucial in breast cancer research.
Article
Oncology
Raffaella Massafra, Agnese Latorre, Annarita Fanizzi, Roberto Bellotti, Vittorio Didonna, Francesco Giotta, Daniele La Forgia, Annalisa Nardone, Maria Pastena, Cosmo Maurizio Ressa, Lucia Rinaldi, Anna Orsola Maria Russo, Pasquale Tamborra, Sabina Tangaro, Alfredo Zito, Vito Lorusso
Summary: Breast cancer mortality is often linked to metastasization and recurrence, emphasizing the need for personalized treatment strategies. A prediction model for Breast Cancer Recurrence within 5 and 10 years after diagnosis showed promising results using machine learning algorithms.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Cristiana Bersaglieri, Raffaella Santoro
Summary: The nucleolus is an important subcompartment in the nucleus responsible for ribosome biogenesis. Recent studies have shown that it also plays a role in organizing the chromosomes in the nucleus. These genomic domains, called nucleolar associated domains (NADs), are characterized by repressive chromatin states. However, accurate identification of NADs has been challenging due to the lack of a membrane.
CURRENT OPINION IN CELL BIOLOGY
(2023)
Article
Oncology
Yang Liu, Tong Yu
Summary: The purpose of this study is to compare and analyze the clinicopathological characteristics and prognosis of patients with invasive ductal carcinoma coexisting with ductal carcinoma in situ (IDC-DCIS) and invasive ductal carcinoma (IDC) in triple-negative breast cancer (TNBC). It was found that there were significant differences in age, family history, menopausal status, KI-67%, lymphovascular invasion, histologic grade of IDC, and multifocal between the two groups. The disease-free survival (DFS) of the IDC-DCIS group was better than that of the IDC group, while the overall survival (OS) did not show a statistically significant difference between the two groups.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Reproductive Biology
Khloud Elsharawy, Mohamed Abou-Dobara, Hekmat El-Gammal, Ayman Hyder
REPRODUCTIVE BIOLOGY
(2020)
Review
Cell Biology
Yousif A. Kariri, Mohammed A. Aleskandarany, Chitra Joseph, Sasagu Kurozumi, Omar J. Mohammed, Michael S. Toss, Andrew R. Green, Emad A. Rakha
Article
Oncology
Khloud A. Elsharawy, Omar J. Mohammed, Mohammed A. Aleskandarany, Ayman Hyder, Hekmat L. El-Gammal, Mohamed I. Abou-Dobara, Andrew R. Green, Leslie W. Dalton, Emad A. Rakha
BRITISH JOURNAL OF CANCER
(2020)
Article
Pathology
Somaia Elsheikh, Ilias Kouzoukakis, Catherine Fielden, Wei Li, Shaimaa Elsaid Lashin, Nadia Khair, Teresa Pereira Raposo, Wakkas Fadhil, Philip Rudland, Mohammed Aleskandarany, Poulam Patel, Mohamed El--Tanani, Mohammad Ilyas
Summary: Ran is an overexpressed poor prognostic marker in malignant melanoma. It promotes cell motility through upregulation of the oncogene c-Met, potentially leading to metastasis.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Article
Cell Biology
Khloud A. Elsharawy, Thomas A. Gerds, Emad A. Rakha, Leslie W. Dalton
Summary: The study evaluated the potential value of AI-based breast cancer grading at the molecular level and in predicting patient outcomes. Results showed that AI grade has promise in predicting patient outcomes, gene discovery, and providing second opinions.
Article
Oncology
Maryam Althobiti, Khloud A. El-sharawy, Chitra Joseph, Mohammed Aleskandarany, Michael S. Toss, Andrew R. Green, Emad A. Rakha
Summary: SLC39A6 may have prognostic value for a better outcome in ER + luminal breast cancer, with high expression being associated with longer BC-specific survival even in patients who did not receive endocrine therapy. Further functional studies on the role of SLC39A6 in ER + luminal breast cancer are warranted.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Yousif Kariri, Michael S. Toss, Mansour Alsaleem, Khloud A. Elsharawy, Chitra Joseph, Nigel P. Mongan, Andrew R. Green, Emad A. Rakha
Summary: The study reveals that UBE2C is an independent prognostic biomarker in invasive breast cancer, with high expression of UBE2C associated with poor prognosis and correlated with other prognostic indicators and tumor characteristics. These findings suggest that UBE2C could be a potential therapeutic target in breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Karuna Mittal, Jaspreet Kaur, Shaligram Sharma, Nivya Sharma, Guanhao Wei, Ishita Choudhary, Precious Imhansi-Jacob, Nagini Maganti, Shrikant Pawar, Padmashree Rida, Michael S. Toss, Mohammed Aleskandarany, Emiel A. Janssen, Havard Soiland, Meenakshi Gupta, Michelle D. Reid, Emad A. Rakha, Ritu Aneja
Summary: Hypoxia promotes centrosome amplification (CA) by upregulating PLK4 via HIF1 alpha. High levels of HIF1A and PLK4 are associated with poor overall survival in breast cancer and PDAC patients, indicating the significance of HIF1 alpha and PLK4 in prognosis. The findings suggest that HIF1 alpha-induced CA through direct upregulation of PLK4 could serve as a potential risk stratification marker and therapeutic target for CA-rich cancers.
MOLECULAR CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Qi Xu, Jaspreet Kaur, Dennis Wylie, Karuna Mittal, Hongxiao Li, Rishab Kolachina, Mohammed Aleskandarany, Michael S. Toss, Andrew R. Green, Jianchen Yang, Thomas E. Yankeelov, Shristi Bhattarai, Emiel A. M. Janssen, Jun Kong, Emad A. Rakha, Jeanne Kowalski, Ritu Aneja
Summary: This study explores the intratumoral heterogeneity (ITH) in triple-negative breast cancer (TNBC) by evaluating gene expression and imaging differences within the same tumor. The results show extensive intertumoral heterogeneity and regional ITH in gene expression and image-derived features in TNBC. Concerns are raised regarding gene expression based TNBC subtyping.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yousif A. Kariri, Chitra Joseph, Mansour A. Alsaleem, Khloud A. Elsharawy, Sami Alsaeed, Michael S. Toss, Nigel P. Mongan, Andrew R. Green, Emad A. Rakha
Summary: Breast cancer exhibits genetic and clinical heterogeneity. This study evaluates the prognostic and biological value of Cell Division Cycle Associated 5 (CDCA5) in breast cancer. The results demonstrate that CDCA5 plays an important role in breast cancer development and metastasis, and could be used as a potential biomarker for disease progression.
Article
Oncology
Abrar Aljohani, Michael S. Toss, Khloud A. El-Sharawy, Sameer Mirza, Graham R. Ball, Andrew R. Green, Emad A. Rakha
Summary: Lymphovascular invasion (LVI) is a crucial step in breast cancer (BC) metastasis, and CCNB2 plays an important regulatory role in LVI. Knockdown of CCNB2 inhibits BC cell migration and proliferation, blocks the cell cycle, and reduces apoptotic cell count. High CCNB2 protein expression is associated with other aggressive behavior features and shorter survival. Therefore, CCNB2 may be a promising therapeutic target to inhibit LVI and reduce metastatic events.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Khloud A. Elsharawy, Maryam Althobiti, Omar J. Mohammed, Abrar I. Aljohani, Michael S. Toss, Andrew R. Green, Emad A. Rakha
Summary: NOP10 is a key factor in ribosome biogenesis and telomere maintenance, and its high expression is significantly associated with aggressive features in breast cancer, especially in the triple-negative breast cancer subtype. High NOP10 protein expression is an independent predictor of poor outcome, shorter survival, and higher risks of death and distant metastasis in chemotherapy-treated patients. This suggests that NOP10 may serve as a potential prognostic biomarker and predictive indicator for chemotherapy resistance in breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Meeting Abstract
Oncology
Sami A. Alsaeed, Mohammed A. Aleskandarany, Sasagu Kurozumi, Chitra Joseph, Mansour Alsaleem, Michael Toss, Nigel P. Mongan, Ian O. Ellis, Andrew R. Green, Emad A. Rakha
BREAST CANCER RESEARCH AND TREATMENT
(2020)
Meeting Abstract
Oncology
Mansour Alsaleem, Chitra Joseph, Pavan Narsimha, Michael Toss, Graham Ball, Sara Raafat, Mohammed Aleskandarany, Angela Ogdon, Padmashree Rida, Andrew Green, Ian Ellis, Ritu Aneja, Nigel Mongan, Emad Rakha
BREAST CANCER RESEARCH AND TREATMENT
(2020)